The Use of Data from Low Frequency Analysis to Illustrate Serial EEG Changes in Depressed Patients During Treatment with Iproniazid

Abstract

Iproniazid, introduced as an anti-tubercular drug, has been widely used in the treatment of depression. It is a monoamine oxidase inhibitor and some of its effect on the central nervous system may therefore depend upon its preventing the breakdown of serotonin. It is hepatotoxic. Dally (2) and many others have commented upon a time lag of at least a week after the start of treatment before observable clinical improvement in depressed patients.